GSK
GSK
741 hedge funds and large institutions have $9.84B invested in GSK in 2017 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 289 increasing their positions, 251 reducing their positions, and 71 closing their positions.
64% more call options, than puts
Call options by funds: $130M | Put options by funds: $79M
15% more repeat investments, than reductions
Existing positions increased: 289 | Existing positions reduced: 251
0.21% more ownership
Funds ownership: 3.74% → 3.95% (+0.21%)
1% less capital invested
Capital invested by funds: $9.91B → $9.84B (-$68.7M)
5% less funds holding
Funds holding: 779 → 741 (-38)
9% less funds holding in top 10
Funds holding in top 10: 11 → 10 (-1)
41% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 71
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
+$602M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$132M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$101M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$39.1M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$33.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$208M |
| 2 |
Millennium Management
New York
|
-$94.9M |
| 3 |
HA
Homestead Advisers
Arlington,
Virginia
|
-$79.9M |
| 4 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$49.9M |
| 5 |
Jane Street
New York
|
-$31M |
GSK Hedge Fund Activity: Q3 2017 in Review
741 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q3 2017, worth a combined $9.84B — down 0.69% from $9.91B a quarter earlier.
Sellers outnumbered buyers: 71 funds closed out of GSK and 42 opened new positions — a net loss of 29 holders — while 251 trimmed existing stakes and 289 added.
The largest buyer was Dodge & Cox, adding an estimated $602M. The largest seller was Fidelity Investments, cutting an estimated $208M.
- 741 institutional investors held GSK (GSK) as of Q3 2017, down from 779 in Q2 2017.
- Funds reported $9.84B of GSK stock for Q3 2017, down 0.69% quarter-over-quarter.
- 42 funds opened new GSK positions in Q3 2017 and 71 closed out, a net change of -29 holders.
- The largest GSK buyer in Q3 2017 was Dodge & Cox, an estimated $602M added.
- The largest GSK seller in Q3 2017 was Fidelity Investments, an estimated $208M sold.
Based on aggregated 13F filings for Q3 2017.